Profile data is unavailable for this security.
About the company
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
- Revenue in USD (TTM)6.39m
- Net income in USD50.68m
- Incorporated2015
- Employees56.00
- LocationPureTech Health PLC6 Tide Street, Suite 400BOSTON 02210United StatesUSA
- Phone+1 (617) 482-2333
- Fax+1 (617) 482-3337
- Websitehttps://puretechhealth.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Forte Biosciences Inc | 0.00 | -51.74m | 402.24m | 16.00 | -- | 4.78 | -- | -- | -4.49 | -4.49 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -89.96 | -64.69 | -110.72 | -71.52 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.71 | -- | -38.72 | -- |
| Lenz Therapeutics Inc | 17.50m | -58.88m | 403.01m | 42.00 | -- | -- | -- | 23.03 | -2.11 | -2.11 | 0.6268 | -- | -- | -- | -- | 416,666.70 | -- | -39.77 | -- | -42.56 | -- | -- | -336.47 | -- | -- | -- | -- | -- | -- | -- | 60.07 | -- | -- | -- |
| Regenxbio Inc | 161.32m | -177.92m | 404.48m | 353.00 | -- | 2.51 | -- | 2.51 | -3.46 | -3.46 | 3.14 | 3.19 | 0.3089 | -- | 6.59 | 456,991.50 | -34.07 | -20.33 | -43.55 | -23.79 | 87.18 | 76.64 | -110.29 | -82.78 | -- | -6.74 | 0.5427 | -- | -7.66 | 18.79 | 13.81 | -- | -26.96 | -- |
| Allogene Therapeutics Inc | 0.00 | -212.02m | 404.51m | 226.00 | -- | 1.27 | -- | -- | -0.981 | -0.981 | 0.00 | 1.41 | 0.00 | -- | -- | 0.00 | -41.21 | -31.11 | -43.96 | -33.14 | -- | -- | -- | -1,187.06 | -- | -- | 0.00 | -- | -76.84 | -- | 21.29 | -- | -57.62 | -- |
| Niagen Bioscience Inc | 124.71m | 20.43m | 410.20m | 104.00 | 21.15 | 5.79 | 19.35 | 3.29 | 0.243 | 0.243 | 1.48 | 0.8875 | 1.61 | 3.07 | 18.34 | 1,199,125.00 | 26.42 | -23.12 | 35.76 | -35.20 | 63.89 | 60.73 | 16.38 | -15.71 | 3.29 | -- | 0.00003 | -- | 19.18 | 16.56 | 273.15 | -- | -26.37 | -- |
| Kyverna Therapeutics Inc | 0.00 | -160.99m | 414.75m | 129.00 | -- | 2.09 | -- | -- | -3.72 | -3.72 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -61.17 | -- | -69.77 | -- | -- | -- | -- | -- | -- | -- | 0.0013 | -- | -- | -- | -111.17 | -- | -- | -- |
| Entrada Therapeutics Inc | 61.52m | -103.46m | 415.83m | 183.00 | -- | 1.22 | -- | 6.76 | -2.50 | -2.50 | 1.47 | 8.91 | 0.1272 | -- | 32.39 | 336,174.90 | -21.39 | -8.44 | -23.70 | -10.02 | -- | -- | -168.16 | -33.36 | -- | -- | 0.00 | -- | 63.38 | -- | 1,081.69 | -- | 38.04 | -- |
| Tectonic Therapeutic Inc | 0.00 | -67.30m | 417.00m | 51.00 | -- | 1.56 | -- | -- | -3.85 | -3.85 | 0.00 | 14.30 | 0.00 | -- | -- | 0.00 | -30.20 | -- | -32.12 | -- | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -35.40 | -- | -- | -- |
| Assembly Biosciences Inc | 37.19m | -38.55m | 421.68m | 73.00 | -- | 2.31 | -- | 11.34 | -4.81 | -4.81 | 4.33 | 11.55 | 0.2186 | -- | 81.56 | 509,465.80 | -22.66 | -41.01 | -31.44 | -47.70 | -- | -- | -103.65 | -319.31 | -- | -- | 0.00 | -- | 298.16 | 12.31 | 34.38 | -- | -55.21 | -- |
| PureTech Health PLC (ADR) | 6.39m | 50.68m | 423.98m | 56.00 | 8.43 | 1.12 | 12.00 | 66.34 | 2.07 | 2.07 | 0.265 | 15.65 | 0.0113 | -- | 2.81 | 114,125.00 | 5.63 | -3.27 | 6.57 | -3.83 | -- | -- | 498.87 | -253.25 | -- | -- | 0.0537 | -- | 44.98 | -13.21 | 181.45 | -33.81 | -75.53 | -- |
| PepGen Inc | 0.00 | -93.56m | 442.74m | 81.00 | -- | 2.71 | -- | -- | -2.84 | -2.84 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -51.93 | -45.06 | -56.56 | -49.76 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.44 | -- | 76.52 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -31.93m | 444.22m | 27.00 | -- | 8.61 | -- | -- | -0.7173 | -0.7173 | 0.00 | 0.9913 | 0.00 | -- | -- | 0.00 | -58.27 | -43.91 | -63.85 | -46.83 | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | -26.12 | -- | 65.72 | -- |
| Zura Bio Ltd | 0.00 | -62.52m | 447.98m | 30.00 | -- | 3.65 | -- | -- | -0.6686 | -0.6686 | 0.00 | 1.66 | 0.00 | -- | -- | 0.00 | -39.10 | -- | -49.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 34.45 | -- | -- | -- |
| Verastem Inc | 13.38m | -241.11m | 449.04m | 78.00 | -- | -- | -- | 33.56 | -4.02 | -4.02 | 0.2209 | -0.2326 | 0.0882 | -- | 3.76 | 171,525.60 | -159.03 | -68.26 | -233.92 | -83.33 | 85.14 | -- | -1,802.12 | -417.53 | 2.55 | -- | 1.21 | -- | -- | -10.54 | -49.53 | -- | 31.95 | -- |
| Lexeo Therapeutics Inc | 0.00 | -104.97m | 460.55m | 72.00 | -- | 2.87 | -- | -- | -2.70 | -2.70 | 0.00 | 2.20 | 0.00 | -- | -- | 0.00 | -66.08 | -- | -76.72 | -- | -- | -- | -- | -- | -- | -- | 0.0084 | -- | -- | -- | -48.11 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to PureTech Health PLC's reporting currency: US Dollar USD
0.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Pentwater Capital Management LPas of 30 Sep 2025 | 75.00k | 0.31% |
| Millennium Management LLCas of 30 Sep 2025 | 17.84k | 0.07% |
| Diadema Partners LPas of 30 Sep 2025 | 7.32k | 0.03% |
| Persistent Asset Partners Ltd.as of 30 Sep 2025 | 1.69k | 0.01% |
| UBS Financial Services, Inc.as of 31 Dec 2025 | 20.00 | 0.00% |
| Portolan Capital Management LLCas of 30 Sep 2025 | 0.00 | 0.00% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
